A therapy derived from a weakened version of a deadly kind of bacteria reduced metastasis of pancreatic cancer in mice with no obvious ill effects, according to a new study.
With a five-year survival rate of less than 5%, pancreatic cancer is aggressive, deadly and an all-but-certain death sentence, in part because it is usually metastasized before doctors spot it. Japanese scientists have come up with a blood test that would screen for certain metabolites to help detect the disease earlier than current diagnostics allow, and potentially boost those survival odds.
The FDA is taking a closer look at the increased risk of Type 2 diabetics getting pancreatic cancer from the popular drugs like Merck's blockbuster Januvia and Byetta from Bristol-Myers Squibb.
A drug that Celgene ($CELG) acquired in its $2.9 billion acquisition of Abraxis BioScience in 2010 is showing promise against the notoriously hard-to-treat p ancreatic cancer.
Celgene CEO Bob Hugin is leading a push to rapidly grow the major drugmaker, keeping the company atop lists of go-to partners among biotechs.
With the 5-year survival rate for pancreatic cancer at just 6%--the lowest among all major killer cancers--finding a treatment for the disease could literally be lifesaving for patients.
The company's cancer drug Abraxane aced a study in pancreatic cancer, boosting patients' survival and forming the foundation for a new FDA approval app.Analysts greeted the data with some impressive sales projections.
They're popping corks at Celgene ($CELG) headquarters. The company's cancer drug Abraxane aced a study in pancreatic cancer, boosting patients' survival and forming the foundation for a new FDA approval app.
Swedish drug developer Kancera says it has slowed the growth of pancreatic cancer tumors in preclinical animal trials with its first-generation PFKFB3 inhibitors.
A Phase III finding of a set of blood biomarkers could lead to a companion diagnostic to be used alongside masitinib, AB Science's investigational drug for pancreatic cancer.